Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2020-08-13
DOI
10.1080/14656566.2020.1803281
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography.
- (2019) Christian Zurth et al. JOURNAL OF CLINICAL ONCOLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)
- (2019) Neal D. Shore et al. Clinical Genitourinary Cancer
- Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
- (2019) E J Small et al. ANNALS OF ONCOLOGY
- Plasma Androgen Receptor in Prostate Cancer
- (2019) Vincenza Conteduca et al. Cancers
- Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography.
- (2018) Christian Zurth et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure
- (2018) Susan Slovin et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
- (2018) Karim Fizazi et al. Clinical Genitourinary Cancer
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
- (2017) Wanling Xie et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
- (2017) Gillian M Duchesne et al. LANCET ONCOLOGY
- The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- (2016) Christopher P. Evans et al. EUROPEAN UROLOGY
- Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
- (2016) Michel Bolla et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
- (2016) Neal D Shore et al. LANCET ONCOLOGY
- Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
- (2016) Gillian M Duchesne et al. LANCET ONCOLOGY
- PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Salvatore L. Burgio et al. Clinical Genitourinary Cancer
- Clinical Pharmacokinetic Studies of Enzalutamide
- (2015) Jacqueline A. Gibbons et al. CLINICAL PHARMACOKINETICS
- Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer
- (2015) Celestia S. Higano et al. EUROPEAN UROLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model
- (2015) Howard I. Scher et al. PLoS One
- Androgen receptor antagonists for prostate cancer therapy
- (2014) Christine Helsen et al. ENDOCRINE-RELATED CANCER
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide
- (2014) Vincenza Conteduca et al. PROSTATE
- An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study
- (2014) L Klotz et al. PROSTATE CANCER AND PROSTATIC DISEASES
- No Androgen Withdrawal Syndrome for Enzalutamide: A Report of Disease Dynamics in the Postchemotherapy Setting
- (2013) Christoph A. von Klot et al. EUROPEAN UROLOGY
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
- (2013) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer
- (2010) Matthew R. Smith et al. CANCER
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
- (2010) William R. Foster et al. PROSTATE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Antiandrogen withdrawal in castrate-refractory prostate cancer
- (2008) A. Oliver Sartor et al. CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started